ERBB2 and breast cancer: The group of Lahoutte et al. used this approach to reduce kidney uptake of Camelid single-domain antibody-fragment (sdAb) 2Rs15d targeting Her2/neu, the human epidermal growth factor receptor 2, which plays a major role in breast cancer and other entities.